NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









GEn1E Lifesciences

GEn1E Lifesciences

Private
Palo Alto, CaliforniaHealthcare & Life Scienceshttps://www.gen1e.com/

Last Round

Grant

Oct 24, 2023

Total Funding Raised

$4M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

GEn1E Lifesciences is a biotechnology company that accelerates the development of next-generation immunomodulatory therapies for rare and inflammatory diseases through an innovative drug development platform that leverages artificial intelligence to create novel therapeutics rapidly.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

drug discoverybiotechnologyAI drug discoverysmall molecule inhibitorsinflammatory diseasesage-related diseasesclinical-stage biotechcomputer-aided drug designCADDimmunomodulatory therapiesclinical endotypingtechbioAI-native biotechp38 MAPK inhibitordrug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

GEn1E Lifesciences Comps

Public and private peers based on sector, stage, and business model.

GEn1E Lifesciences comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

GEn1E Lifesciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantOct 24, 2023
VC RoundDec 6, 2022
SeedMar 31, 2020
SeedAug 21, 2019

Key People

Founding team and executive leadership

Ritu Lal

CEO And Co-Founder

Founding Team

GEn1E Lifesciences Investors

Notable investors and investment history

GEn1E Lifesciences investors
InvestorRounds
StartXSeed
Khosla VenturesSeed, VC Round
GaingelsVC Round
Inflect HealthSeed, VC Round
Public Health Emergency Medical Countermeasures EnterpriseGrant
Clear VenturesSeed, VC Round
Y CombinatorSeed, VC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 13, 2026

    Monthly visitors increased 65% MoM.

GEn1E Lifesciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

GEn1E Lifesciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about GEn1E Lifesciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersPalo Alto, California
Employee Range20
Year Founded2018
Last FundingOct 24, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.